IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by Raymond James & Associates

Raymond James & Associates lessened its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 4.7% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 794,957 shares of the medical research company’s stock after selling 39,358 shares during the quarter. Raymond James & Associates owned approximately 0.44% of IQVIA worth $201,037,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in IQV. Norges Bank acquired a new stake in IQVIA during the fourth quarter worth approximately $383,705,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main boosted its holdings in shares of IQVIA by 339.6% during the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 2,067,195 shares of the medical research company’s stock worth $478,308,000 after purchasing an additional 1,597,003 shares during the last quarter. AMF Tjanstepension AB purchased a new stake in shares of IQVIA in the third quarter valued at $148,096,000. Morningstar Investment Services LLC increased its stake in IQVIA by 96.9% in the fourth quarter. Morningstar Investment Services LLC now owns 1,231,916 shares of the medical research company’s stock valued at $286,704,000 after purchasing an additional 606,333 shares during the last quarter. Finally, Capital Research Global Investors lifted its position in IQVIA by 42.2% during the fourth quarter. Capital Research Global Investors now owns 1,995,269 shares of the medical research company’s stock worth $461,675,000 after buying an additional 592,372 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

Insider Buying and Selling at IQVIA

In other news, insider Eric Sherbet sold 1,000 shares of the business’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $241.50, for a total value of $241,500.00. Following the completion of the sale, the insider now directly owns 20,836 shares in the company, valued at approximately $5,031,894. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In related news, insider Kevin C. Knightly sold 8,607 shares of the stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $250.17, for a total transaction of $2,153,213.19. Following the sale, the insider now owns 5,251 shares in the company, valued at $1,313,642.67. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Eric Sherbet sold 1,000 shares of IQVIA stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $241.50, for a total value of $241,500.00. Following the completion of the transaction, the insider now owns 20,836 shares of the company’s stock, valued at $5,031,894. The disclosure for this sale can be found here. Insiders have sold 41,285 shares of company stock worth $10,331,003 over the last quarter. 1.60% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

IQV has been the subject of a number of research analyst reports. SVB Leerink assumed coverage on shares of IQVIA in a research note on Monday, February 26th. They set an “outperform” rating and a $290.00 price objective for the company. StockNews.com raised shares of IQVIA from a “hold” rating to a “buy” rating in a research note on Friday, February 16th. UBS Group boosted their price objective on shares of IQVIA from $240.00 to $300.00 and gave the company a “buy” rating in a research note on Thursday, February 15th. BTIG Research assumed coverage on IQVIA in a research report on Tuesday, February 13th. They issued a “buy” rating and a $285.00 target price on the stock. Finally, Truist Financial boosted their price target on IQVIA from $286.00 to $297.00 and gave the company a “buy” rating in a research report on Tuesday, February 27th. Three research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat.com, IQVIA currently has an average rating of “Moderate Buy” and an average target price of $256.80.

IQVIA Stock Up 0.4 %

Shares of IQVIA stock traded up $0.90 on Friday, hitting $234.88. 697,640 shares of the company’s stock traded hands, compared to its average volume of 761,918. The company has a quick ratio of 0.86, a current ratio of 0.86 and a debt-to-equity ratio of 2.12. The firm’s 50-day moving average is $245.28 and its 200 day moving average is $223.02. The stock has a market cap of $42.63 billion, a P/E ratio of 32.22, a PEG ratio of 2.26 and a beta of 1.50. IQVIA Holdings Inc. has a 52-week low of $167.42 and a 52-week high of $261.73.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Wednesday, February 14th. The medical research company reported $2.84 earnings per share for the quarter, topping the consensus estimate of $2.82 by $0.02. The company had revenue of $3.87 billion during the quarter, compared to analyst estimates of $3.80 billion. IQVIA had a net margin of 9.06% and a return on equity of 29.32%. The firm’s revenue for the quarter was up 3.5% compared to the same quarter last year. During the same period last year, the business earned $2.54 EPS. Equities analysts anticipate that IQVIA Holdings Inc. will post 10.12 earnings per share for the current year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.